Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Limitations of current therapies

11 evidence topics · 34 sources

Summary: undertreatment, route of administration, persistence, and access
  • Undertreatment: from 2003 through 2011, 23.6% to 35.5% of people with moderate psoriasis and 9.4% to 29.7% with severe psoriasis were untreated, 52.3% of those with psoriasis were dissatisfied with their treatment, and among those treated, 29.5% with moderate and 21.5% with severe psoriasis received topical agents alone. Of an estimated 1.7 million insured U.S. patients with moderate to severe psoriasis, 1 million (59%) were not treated in the preceding year, 807,000 had lapsed treatment, and 547,000 were treatment-naive; 40.9% were receiving therapy in the 12 months up to September 2012, and 22.5% of those treated received a biologic. In another study, more than 80% of psoriasis patients with ≥ 4 palms body surface area received no treatment or topical treatment only, and 45% had not seen a physician in a year.
  • Route of administration: respondents in one preference study were willing to accept a reduction from approximately 70% to 40% in the proportion achieving clear or almost-clear skin to avoid injections at home and use a topical treatment. In a survey of 178 patient and 43 dermatologist respondents, both groups preferred oral to injectable treatments for moderate disease when attributes were held equal, and patients with higher needle fear were more likely to favor an oral treatment. Biologics are available only by injection or infusion. In the joint AAD-NPF phototherapy guideline, narrowband UVB is recommended 3 times weekly in the treatment phase, and travel to a phototherapy center can be a limiting factor.
  • Persistence and switching: a meta-analysis of fifty-five studies estimated the proportions adherent and persistent to biological therapy at 0.61 (95% CI 0.48–0.73) and 0.63 (0.57–0.68), highest for ustekinumab and lowest for etanercept. Among 7997 biologic-treated people, switch rates were 14.4% at 12 months and 26.0% at 24 months; IL-23 inhibitors had the lowest risk of switching, with 8.5% for risankizumab and 15.7% for guselkumab over 24 months. The British Association of Dermatologists decision aid, drawing on UK real-world data, gives the likelihood of staying on treatment for more than 1 year as 67–73% for etanercept, 74–76% for adalimumab, 84–86% for ustekinumab, and 85–90% for guselkumab. Of 8,710 biologic-treated people, 11.5% switched and 31.1% discontinued, and switchers had higher adjusted total health care costs than nonswitchers (mean difference $10,120).
  • Access: inability to obtain adequate insurance coverage was among the top reasons for discontinuing biological agents. Insurance plans in the USA often require patients to try and fail other treatments first (step therapy), a process that “often delays access to medically necessary treatments”. Several labels limit the indicated population: cyclosporine to severe, recalcitrant plaque psoriasis after failure of at least one systemic therapy or when other systemic therapies are contraindicated or not tolerated, brodalumab to patients who have failed to respond or lost response to other systemic therapies and only through a REMS program, and adalimumab and infliximab to patients for whom other systemic therapies are medically less appropriate.
Summary: efficacy of oral agents relative to biologics, safety warnings, and monitoring
  • Efficacy in network meta-analyses: in a network meta-analysis of 204 studies with 67,889 randomized participants, anti-IL17, anti-IL12/23, anti-IL23, and anti-TNF-alpha biologics showed a higher proportion of participants reaching PASI 90 than non-targeted and targeted systemic agents. At class level, the PASI 90 RR for anti-IL17 treatment was 3.20 versus TYK-2 inhibitors, 4.01 versus non-targeted systemic treatments, and 5.82 versus phosphodiesterase-4 inhibitors. Deucravacitinib and risankizumab were more effective than apremilast, and ciclosporin and methotrexate were superior to apremilast for PASI 90. A second network meta-analysis, of 60 trials, estimated PASI 90 at 10 to 16 weeks from baseline at 12.1% for apremilast and 11.4% for dimethyl fumarate, against 17.9% for etanercept, 43.7% for adalimumab, 43.9% for ustekinumab, 70.8% for ixekizumab, and 71.6% for risankizumab-rzaa. A review states that deucravacitinib was superior to apremilast and inferior to risankizumab.
  • Limits of the comparative evidence: the network meta-analysis evidence is limited to induction therapy (outcomes from 8 to 24 weeks after randomisation), its participants had a mean age of 44.4 years and a baseline PASI of 20.5, and its serious adverse event analyses rested on a very low number of events. The guideline group of the EuroGuiDerm-adapted German S3 guideline stated it was not able to sufficiently differentiate recommendation levels for individual agents on PASI 90 and serious adverse events alone.
  • Conventional oral agents: methotrexate achieved PASI 75 in 35.5% of patients against 79.6% with adalimumab, and acitretin 50 mg/d achieved PASI 75 in 23% after 8 weeks. Cyclosporine, methotrexate, and acitretin are described as having “limited efficacy and/or are associated with serious side effects and major monitoring requirements”.
  • Safety warnings: the labels of adalimumab, etanercept, infliximab, and certolizumab pegol state an increased risk of serious infections that may lead to hospitalization or death, and the adalimumab label reports lymphoma and other malignancies in children and adolescents treated with TNF blockers. The JYLAMVO (methotrexate) label reports serious adverse reactions including death, and hepatotoxicity risk that generally occurs after a cumulative dose of 1.5 g or more. Cyclosporine can cause hypertension and nephrotoxicity (cyclosporine nephropathy in 18/86 [21%] of biopsied psoriasis patients). Acitretin must not be used by females who are pregnant or intend to become pregnant during therapy or for at least 3 years after discontinuation. Suicidal ideation and behavior, including completed suicides, have occurred with brodalumab, and bimekizumab carries a warning for suicidal ideation and behavior; oral candidiasis occurred in 19.3% with bimekizumab and 3.0% with secukinumab. The AAD-NPF biologics guideline recommends avoiding IL-17 inhibitors in patients with a personal history of or active IBD. With apremilast, depression was reported in 1.3% vs. 0.4% with placebo and weight decrease of 5%-10% in 12% vs. 5%, and diarrhea and nausea each occurred in 17%. The deucravacitinib label warns of infections, CPK elevation and rhabdomyolysis, and triglyceride elevations, and a review describes deucravacitinib as the only JAK or TYK2 inhibitor indicated for psoriasis that “does not have a boxed warning”. Class 1 topical corticosteroids are limited to up to 4 weeks, and tachyphylaxis may occur with use beyond 12 weeks.
  • Screening and monitoring: deucravacitinib requires evaluation for active and latent tuberculosis before treatment and periodic evaluation of serum triglycerides; for icotrokinra, tuberculosis evaluation is considered based on clinical judgement and live vaccines are avoided. The adalimumab label directs monitoring of all patients for active tuberculosis during treatment, even if the initial latent test is negative; cyclosporine requires frequent monitoring of serum creatinine; the EuroGuiDerm-adapted guideline group monitors methotrexate with transaminases; and periodic assessment of suicidal ideation is recommended with brodalumab. Apremilast has no requirement for laboratory monitoring.
Injection burden and preference for oral administration
Network meta-analysis evidence limited to induction-phase outcomes and trial populations